

1 **Primary exposure to Zika virus increases risk of symptomatic dengue virus infection with**
2 **serotypes 2, 3, and 4 but not serotype 1**

3

4 Jose Victor Zambrana^{1,2,†}, Chloe M. Hasund^{3,†}, Rosemary A. Aogo^{3,†}, Sandra Bos⁴, Sonia

5 Arguello¹, Karla Gonzalez^{1,5}, Damaris Collado¹, Tatiana Miranda¹, Guillermina Kuan^{1,6}, Aubree

6 Gordon², Angel Balmaseda^{1,5}, Leah Katzelnick^{3*}, Eva Harris^{4*}

7 [†]These authors contributed equally.

8 ^{*}Co-corresponding authors. Leah Katzelnick (leah.katzelnick@nih.gov) and Eva Harris
9 (eharris@berkeley.edu).

10

11 ¹Sustainable Sciences Institute; Managua, Nicaragua

12 ²Department of Epidemiology, School of Public Health, University of Michigan; Ann Arbor, MI,
13 USA

14 ³Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of
15 Allergy and Infectious Diseases, National Institutes of Health, Bethesda; MD, USA

16 ⁴Division of Infectious Disease and Vaccinology, School of Public Health, University of
17 California, Berkeley; Berkeley, CA, USA

18 ⁵Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
19 Salud; Managua, Nicaragua

20 ⁶Centro de Salud Sócrates Flores Vivas, Ministerio de Salud; Managua, Nicaragua

21

22 **One-Sentence Summary:** Dengue disease risk is differentially modulated depending on pre-
23 existing immunity to dengue and Zika virus infections and the secondary infecting serotype.

24

25 **ABSTRACT**

26 Infection with any of the four dengue virus serotypes (DENV1-4) can protect against or enhance
27 subsequent dengue depending on pre-existing antibodies and the subsequent infecting serotype.
28 Additionally, primary infection with the related flavivirus Zika virus (ZIKV) has been shown to
29 increase DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced
30 risk of disease caused by all four serotypes in a pediatric Nicaraguan cohort. Of 3,412
31 participants in 2022, 10.6% experienced symptomatic DENV infections caused by DENV1
32 (n=139), DENV4 (n=133), DENV3 (n=54), DENV2 (n=9), or an undetermined serotype (n=39).
33 Longitudinal clinical and serological data were used to define infection histories, and generalized
34 linear and additive models adjusted for age, sex, time since the last infection, cohort year, and
35 repeat measurements were used to predict disease risk. Compared to flavivirus-naïve
36 participants, primary ZIKV infection increased disease risk of DENV4 (relative risk = 2.62, 95%
37 confidence interval: 1.48-4.63) and DENV3 (2.90, 1.34-6.27) but not DENV1 (1.20, 0.72-1.99).
38 Primary DENV infection or a DENV followed by ZIKV infection also increased DENV4 risk.
39 We re-analyzed 19 years of cohort data and demonstrated that prior flavivirus-immunity and pre-
40 existing antibody titer differentially affected disease risk for incoming serotypes, increasing risk
41 of DENV2 and DENV4, protecting against DENV1, and protecting at high titers but enhancing
42 at low titers against DENV3. We thus find that prior ZIKV infection, like prior DENV infection,
43 increases risk of certain DENV serotypes. Cross-reactivity among flaviviruses should be
44 carefully considered when assessing vaccine safety and efficacy.

45 INTRODUCTION

46 Dengue virus, comprised of four distinct serotypes (DENV1-4), and Zika virus (ZIKV) are
47 antigenically related, mosquito-borne flaviviruses that cause a significant global health burden
48 (1-3). Both flaviviruses are transmitted by female *Aedes aegypti* mosquitoes, co-circulate in
49 many countries, and cause major epidemics worldwide (1). DENV and ZIKV infection each
50 induce antibodies that cross-react with the other viruses, but how these antibodies modulate
51 subsequent disease risk has only been partially elucidated (4, 5).

52

53 Following a DENV or ZIKV infection, neutralizing antibodies at high titers are observed to
54 provide long-lasting protection against the infecting virus, a phenomenon termed homotypic
55 protection (6). Cross-reactive neutralizing antibodies can provide protection against an incoming
56 heterotypic infection (7-9). However, DENV infection also elicits low-to-intermediate cross-
57 reactive antibody titers, which can increase risk of a symptomatic infection and enhance disease
58 severity in a subsequent DENV infection with a different serotype (10-13). This increased risk
59 has been attributed to a phenomenon known as antibody-dependent enhancement (ADE),
60 whereby non- or poorly neutralizing antibodies facilitate DENV entry into host cells through the
61 Fc γ receptor, improving infection efficiency and activating target immune cells (14, 15).
62 Increased risk of future dengue disease severity following a DENV infection is well established
63 (11, 14, 16), and two studies have reported an association between prior ZIKV infection and
64 DENV2 disease risk (17, 18). This last finding is consistent with studies in macaques exposed to
65 ZIKV and then DENV2, which have shown an increase in viremia compared to ZIKV-naïve
66 macaques (19, 20). It is unclear whether primary ZIKV infection modulates secondary dengue
67 caused by other serotypes.

68
69 Symptomatic and severe disease occur more frequently in secondary DENV2 and DENV4
70 infections, as compared to DENV1 and DENV3 infections (10, 11, 21-24). In line with this
71 observation, a higher neutralizing antibody titer is needed to protect against symptomatic
72 DENV2 versus other serotypes (9, 23, 25). We previously showed that a broad range of pre-
73 existing anti-DENV binding antibody titers can enhance DENV2 disease, low titers can enhance
74 DENV3, and high titers protect against DENV1 and DENV3 (26). Less is known about the effect
75 of pre-existing antibody titer on DENV4.

76
77 In 2022, all four DENV serotypes co-circulated in Nicaragua in populations affected by the 2016
78 Zika epidemic. This large dengue epidemic (n=374 cases) in the Nicaraguan Pediatric Cohort
79 Study enabled us to evaluate whether prior ZIKV and DENV infections modulate risk of
80 secondary dengue caused by DENV1, DENV3, or DENV4. We also evaluated whether
81 individuals with a prior DENV infection followed by a ZIKV infection (DENV-ZIKV) had
82 similar outcomes as individuals with a primary ZIKV infection followed by DENV infection
83 (ZIKV-DENV), a group observed for the first time in the Nicaraguan cohort. Further, we
84 measured the effect of flavivirus immunity and pre-existing DENV antibody titers on
85 symptomatic DENV1-4 infection over 19 years of cohort data and performed a mediation
86 analysis to examine the relative contribution of antibody titer to the relationship between
87 infection history and DENV infection outcome. Finally, we evaluated the long-term antibody
88 kinetics in individuals with varied flavivirus infection histories.

89

90

91 **RESULTS**

92 **All four DENV serotypes co-circulated during the 2022-2023 dengue epidemic in**
93 **Nicaragua, and prior DENV or ZIKV infections increase risk of dengue cases**

94 The Pediatric Dengue Cohort Study has followed ~4,000 participants ages 2-17 years for
95 arbovirus infection in Managua, Nicaragua, continuously since 2004 (table S1). In 2022, for the
96 first time since the cohort was established, all four DENV serotypes were detected in cases,
97 circulating simultaneously (Fig. 1A). A total of 10.6% of all participants experienced
98 symptomatic DENV infections; 374 cases met the dengue case definition and were confirmed by
99 RT-PCR or paired acute and convalescent serology of the 3,412 active cohort participants with
100 complete infection histories. Most infections were caused by DENV1 (n=139) and DENV4
101 (n=133), followed by DENV3 (n=54) and DENV2 (n=9), and a subset were confirmed by
102 serology (n=39) (Table 1).

103

104 Before the 2022-2023 epidemic in Nicaragua, the ZIKV pandemic affected the cohort in 2016,
105 followed by a large DENV2 epidemic in 2019, with minimal flavivirus circulation observed
106 between these epidemics. Further, DENV2 was the only serotype detected in cases between 2014
107 and 2021. Thus, based on the young ages of the cohort, nearly half of participants (n=48.6%)
108 were only ever exposed to ZIKV or DENV2. In 2022, 45.7% of the cohort were flavivirus-naïve,
109 21.7% had experienced only a prior ZIKV infection, 8.8% had only had one prior DENV
110 infection, and 23.8% had experienced different combinations of DENV and ZIKV infections
111 (Fig. 1B). Notably, DENV seropositivity and population anti-DENV antibody titers declined
112 after the DENV3 epidemic in 2010-2011, titers increased after the ZIKV epidemic in 2016, and
113 seropositivity and titers increased again after the DENV2 epidemic in 2019-2020 (Fig. 1B and

114 1C).

115

116 During the 2022-2023 dengue epidemic, the overall risk of experiencing a dengue case was 7.8%
117 (6.7%-9.4%) for the flavivirus-naïve group, our reference group, and was significantly higher for
118 participants with one prior ZIKV infection (risk = 14.8%, 12.5%-17.6%), two prior DENV
119 infections (DENV-DENV) (19.0, 11.4%-31.7%), and one prior DENV and then ZIKV infection
120 (DENV-ZIKV) (14.4%, 10.0%-20.7%) (fig. S1). We were unable to calculate risk for some of
121 the more complex infection histories, including those with different sequences of DENV and
122 ZIKV infections followed by DENV infection (DENV-ZIKV-2+DENV, ZIKV-DENV-DENV,
123 and 2+DENV-ZIKV-DENV), because of low numbers of individuals in these groups and lack of
124 any symptomatic DENV infections.

125

126 **Primary DENV and ZIKV infection increases risk of symptomatic infection caused by**
127 **DENV2 and DENV4 but not DENV1, while primary ZIKV infection also increases risk of**
128 **symptomatic DENV3 infection**

129 To investigate the role of infection history on outcome by serotype, we first evaluated whether
130 primary ZIKV infection increased the risk of symptomatic infections caused by DENV1,
131 DENV3, and DENV4 during the 2022-2023 epidemic. Only 9 DENV2 cases were detected in
132 2022, thus we could not analyze DENV2 case risk by infection histories. Using log-binomial
133 generalized linear models (GLMs) adjusted for age, sex, and time since previous infection, we
134 found that primary ZIKV infection significantly increased the risk of symptomatic DENV
135 infection compared to flavivirus-naïve individuals (Risk Ratio (RR) = 1.61, 95% CI: 1.20-2.17).
136 When these analyses were stratified by infecting serotype, risk of disease was increased for

137 DENV3 (RR = 2.90, 1.34-6.27) and DENV4 (RR = 2.62, 1.48-4.63), but not DENV1 (Fig. 2A
138 and table S2). Children with a prior ZIKV infection also trended toward increased risk of dengue
139 with warning signs or severe dengue (DwWS/SD) (RR=2.19, 0.99: 4.83, $p = 0.053$) compared to
140 flavivirus-naïve children.

141
142 To increase statistical power and resolution and to include DENV2, we performed the above
143 analyses on data from the entire Pediatric Dengue Cohort Study timeframe (2004 to 2023). We
144 used both log-binomial and log-poisson generalized linear mixed-effect models (GLMMs)
145 adjusted for age, sex, time since last infection, and cohort epidemic year, with clustering at the
146 individual level to account for repeat measurements. Similar to observations for the 2022-2023
147 epidemic, we found that compared to flavivirus-naïve individuals, a prior ZIKV infection
148 significantly increased the risk of symptomatic dengue overall (RR=1.87, 1.54-2.27) as well as
149 the risk of DwWS/SD (RR = 3.62, 2.44-5.38) (Fig. 2B and table S3). Primary ZIKV infection
150 significantly increased the risk for a subsequent DENV2, DENV3, and DENV4 infection, but not
151 DENV1.

152
153 We performed the same analyses for participants with primary DENV infection. When analyzed
154 across cohort years, primary DENV infection significantly increased the risk of symptomatic
155 DENV2 (RR = 2.09, 1.44-3.05) and DENV4 (RR = 3.28, 1.64-6.57) infections, but not DENV1
156 or DENV3 infections (Fig. 2B and table S3). Unlike a prior ZIKV infection, a single prior
157 DENV infection did not increase risk of symptomatic dengue overall (RR = 1.17, 0.94-1.45);
158 however, one prior DENV infection did increase overall risk of DwWS/SD (RR = 1.67, 1.09-
159 2.57), although not as much as prior ZIKV (Fig. 2B and table S3).

160

161 **The number and order of DENV and ZIKV infections determine risk of developing future**

162 **dengue**

163 Sequential infection with different DENV serotypes is thought to protect against disease by
164 inducing broadly protective antibodies against all serotypes (27). We previously found that
165 individuals with primary DENV infection followed by a ZIKV infection (DENV-ZIKV) were at
166 increased risk of subsequent symptomatic DENV2 infection compared to being flavivirus-naïve,
167 suggesting that the additional ZIKV infection did not broaden their protective immunity (26).
168 Here, we compared dengue disease risk for DENV-ZIKV infection histories to children with a
169 previously unobserved sequence of infections: ZIKV followed by one DENV infection (ZIKV-
170 DENV). In the analysis of all epidemic seasons, the DENV-ZIKV infection history was found to
171 significantly increase the risk of subsequent symptomatic dengue overall (RR = 1.47, 1.09-1.99)
172 and specifically, subsequent symptomatic infection with DENV2 (RR = 2.53, 1.64-3.91) and
173 DENV4 (RR = 4.05, 1.93-8.49), as well as DwWS/SD (RR = 3.26, 1.94-5.50) (Fig. 2B and table
174 S3). In contrast, the ZIKV-DENV infection sequence did not increase the risk of future
175 symptomatic DENV1-4 infections, dengue disease, or DwWS/SD (Fig. 2A and 2B, table S2 and
176 S3).

177

178 Counter to our expectation, we also found that across epidemic seasons, those with two prior
179 DENV infections (DENV-DENV) were at increased risk of subsequent symptomatic dengue
180 overall (RR=2.66, 1.49-4.76) and DwWS/SD (3.62, 2.44-5.38) compared to the flavivirus-naïve
181 group (Fig. 2A and 2B, tables S2 and S3). The DENV-DENV group was also at a greater risk of
182 symptomatic DENV3 infection (RR = 2.40, 1.37-4.23) (Fig. 2B and table S3). However, those

183 with two or more DENV infections (2+DENV group) or at least two DENV infections and a
184 ZIKV infection (2+DENV-ZIKV) were not at increased risk of either symptomatic or severe
185 dengue (Fig. 2B and table S3). Protective effects were only observed for the 2+ DENV group
186 against symptomatic DENV infection overall (RR = 0.64, 0.48-0.86), and DENV1 (RR = 0.41,
187 0.22-0.79). Individuals with multiple flavivirus infections may live in high-risk areas for
188 exposure to DENV. We thus performed a sensitivity analysis where we controlled for the age-
189 adjusted DENV seroprevalence at the neighborhood level in the year prior to the recorded
190 dengue case for each participant and clustered participants by neighborhood. Results were
191 similar to our previous results (Fig. 2) for both the 2022-2023 epidemic season and the complete
192 cohort epidemic seasons (2004-2023) across infection histories, suggesting that spatial risk did
193 not explain the increased risk of disease observed for the DENV-DENV group (fig. S2).

194
195 We investigated when the 12 individuals with dengue cases in 2022-2023 in the DENV-DENV
196 group experienced their previous infection to determine the likely prior infecting serotype. Most
197 of those with tertiary DENV4 cases had their second infection three years previously, during the
198 DENV2 epidemic, whereas most DENV1 tertiary cases had experienced their second infection in
199 2021, right before 2022 epidemic when multiple serotypes may have already been circulating
200 (fig. S3). While some sequential infections detected by DENV iELISA in previous years may
201 have been due to homotypic re-exposure, the epidemiology of dengue in the cohort makes it
202 likely that those experiencing tertiary infections in 2022-2023 were infected with distinct
203 serotypes.

204
205 Of note, consistent with previous findings, older age was a significant risk factor for dengue

206 disease as well as for symptomatic DENV1, DENV2 and DENV4 infections in the full cohort
207 analysis. Sex was not a significant factor except with DENV4, where male sex was associated
208 with reduced risk of symptomatic infection in both analyses (Fig. 2A and 2B). Time since
209 infection was not a significant risk factor in any model, except for a slightly increased risk of
210 DENV3 in the complete cohort analysis (Fig. 2A and 2B).

211
212 **Pre-existing flavivirus immunity and antibody titers protect against DENV1, but can**
213 **increase risk of DENV2, DENV3, and DENV4**

214 Across infection histories, we observed increased risk of DENV2, DENV3, and DENV4 disease
215 and DwWS/SD and protective effects against symptomatic DENV1 infection, comparing to
216 flavivirus-naïve individuals. To explore how overall flavivirus immunity affected disease caused
217 by each serotype, we grouped individuals with any prior DENV or ZIKV infection, regardless of
218 serotype or number of infections, as “flavivirus-immune” and the non-exposed as “flavivirus-
219 naïve.” Compared to flavivirus-naïve individuals, those who were flavivirus-immune were at
220 significantly increased risk of dengue disease ($p < 0.001$), DwWS/SD ($p < 0.001$), and
221 DHF/DSS ($p < 0.001$) (Fig. 3 and table S4). However, distinct risks were observed for different
222 serotypes, with significant risk for flavivirus-immune participants of DENV2 ($p < 0.001$) and
223 DENV4 disease ($p = 0.002$), but not DENV3 ($p = 0.551$). Conversely, flavivirus-immune
224 individuals were at significantly lower risk of DENV1 ($p = 0.036$), indicating protection (Fig. 3
225 and table S5).

226
227 We previously showed that pre-existing antibodies, as measured by iELISA (12), can protect or
228 enhance dengue disease and disease severity depending on the titer magnitude and secondary

229 infecting serotype (12, 26). With the recent circulation of DENV4 in the region, we were also
230 able to test how pre-existing anti-flavivirus antibodies modulate all four serotypes, both for the
231 2022 epidemic (Fig. 4A) and across all cohort years (Fig. 4B). Here, we found that DENV
232 iELISA titers (except those >1280) significantly increased risk of symptomatic DENV4 infection
233 compared to flavivirus-naïve children. This effect paralleled that seen for DENV2 in our full
234 cohort analyses. The pattern was different for DENV3, where low titers (<21) increased disease
235 ($p=0.005$) while high titers were protective in the full cohort analyses. Finally, no enhancing
236 effects were observed against DENV1, while higher titers of pre-existing anti-DENV antibodies
237 were protective ($p=0.041$), as seen against DENV3 (Fig. 4A and table S3). Regarding the overall
238 risk of dengue disease and DwWS/SD, we found that low iELISA titers were associated with
239 increased risk of both symptomatic DENV infection and DwWS/SD (Fig. 4 A and B, table S5
240 and S6).

241

242 **Antibody titers strongly explain the relationship between infection history and dengue risk**

243 Based on our observations, we hypothesized that the effect of specific DENV and ZIKV
244 infection histories on the risk of dengue is partially mediated (i.e., explained by) pre-existing
245 DENV iELISA titers. Using a well-established approach, the mediation model, we tested the
246 degree to which each infection history influences dengue disease outcome 1) directly, meaning
247 the infection history itself affected outcome, versus 2) indirectly, meaning infection history
248 modified antibody titers, which in turn modulated disease outcome. We analyzed the 2022-2023
249 epidemic season, and our models were adjusted for time since last infection, age, and sex. We
250 separately tested the mediating effect of iELISA titers within a range previously identified as
251 enhancing (10-320 vs. lower or higher titers) as opposed to protective (>320 vs. ≤ 320).

252 Consistently, every infection history induced antibodies in the range of 10-320 that were
253 associated with increased risk of dengue (Fig. 5A). Titers between 10-320 explained a smaller
254 fraction (<25%) of the total effect of DENV-DENV, ZIKV-DENV and 2+DENV infection
255 histories on dengue outcome, while antibodies in this range explained a larger fraction of the
256 effect of DENV, DENV-immune, ZIKV, DENV-ZIKV, and 2+DENV-ZIKV infection histories
257 (Fig. 5A). Additionally, ZIKV infection had a direct effect (independent of titer) on increasing
258 dengue risk, while the 2+DENV history had a direct protective effect. Conversely, when we
259 tested whether titers greater than 320 (as compared to lower titers) mediated the relationship
260 between infection history and dengue outcome, we found that high antibody titers showed a
261 trend toward protection against symptomatic DENV infection, although this effect was not
262 significant. High antibody titers explained almost all of the effect on dengue outcome for ZIKV-
263 DENV history and almost none of the effect for the ZIKV group, while for other histories, titer
264 explained about a quarter of the effect (Fig. 5B). ZIKV, DENV-DENV, and DENV-ZIKV still
265 retained direct effects on increasing dengue risk. Notably, for infection histories that predisposed
266 individuals to a greater risk of symptomatic DENV infection, such as DENV-DENV, high
267 antibodies decreased their risk probabilities, although not significantly (Fig. 5B). On the
268 contrary, for those categories with less risk, including 2+DENV or ZIKV-DENV, antibodies
269 increased protection against symptomatic DENV infection (Fig. 5B).

270

271 **Order of infecting DENV and ZIKV infections modifies antibody magnitude and kinetics**

272 Cross-reactive anti-DENV antibody titers are modulated both by time since last infection and
273 infection history. We have previously shown that anti-DENV antibodies measured by the DENV
274 iELISA are stable or increase over time after a primary DENV and ZIKV infection and wane

275 after secondary DENV or sequential DENV and ZIKV infections (28). Here, we characterized
276 the magnitude and kinetics of anti-DENV antibodies in previously reported infection histories
277 (28), and for the first time, in individuals with ZIKV-DENV infection histories. We noted
278 differences in the magnitude of the iELISA antibody response measured in the annual sample
279 after infection. Primary ZIKV infection induced the lowest antibody titers, followed by a primary
280 DENV infection (Fig. 6 and table S6). Interestingly, the ZIKV-DENV group on average had 1.1-
281 fold higher titers ($p=3.2e-10$) than the DENV-ZIKV group at the same timepoint (Fig. 6 and
282 table S7), suggesting order of infection has a modest effect on the magnitude of cross-reactive
283 anti-DENV antibodies. After a primary ZIKV infection, antibodies increased (half-life, $t_{1/2}$: 2.31
284 years, 95% CI: 2.10-2.48) for three years, and then gradually declined ($t_{1/2}$: 3.65 years, 3.01-
285 4.33), whereas after a primary DENV infections antibodies were stable (Fig. 6 and table S7). We
286 also found that after sequential DENV or DENV and ZIKV infections, on average, antibodies
287 initially wane rapidly in the first ~2 years, with a subsequent gradual waning or stabilization. In
288 particular, the ZIKV-DENV group was still experiencing rapid waning at the last timepoint
289 measured, suggesting this infection history may be less protective long-term if their antibodies
290 continue to wane.

291

292

293 **DISCUSSION**

294 Our study presents novel insights into the complex interplay between the immune responses to
295 DENV and ZIKV infections and their clinical and epidemiological outcomes. To our knowledge,
296 this is the first study in humans to demonstrate that primary ZIKV infection increases risk of
297 subsequent dengue disease in a serotype-dependent manner. We also show that DENV-ZIKV

298 infection histories are associated with increased risk of symptomatic DENV2 and DENV4
299 infection, while ZIKV-DENV infection history is not. Pre-existing antibody titers were found to
300 modulate disease risk depending on the incoming serotype. Finally, we show that most infection
301 histories can elicit both enhancing and protective antibodies, and their relationship to DENV
302 infection outcome is strongly dependent on antibody titer.

303

304 We have previously shown that a prior ZIKV infection increased risk of symptomatic and severe
305 DENV2 (26). Here, using data from 374 cases in the 2022-2023 epidemic, we show that primary
306 ZIKV infection also increased the risk of symptomatic DENV3 and DENV4 infections and
307 overall disease severity. Intriguingly, a prior ZIKV infection was not a risk factor for
308 symptomatic DENV1 infection. This matched our analysis showing that primary DENV
309 infection is a risk factor for severe disease and symptomatic DENV2 and DENV4 infections
310 across all cohort years. The enhancing effect of ZIKV has now been observed in two separate
311 epidemics and against multiple DENV serotypes in Nicaragua. A separate study in Brazil of 879
312 dengue cases, >99% of which were caused by DENV2, similarly found that individuals with only
313 prior ZIKV infection were more likely to experience severe disease and hospitalization than
314 flavivirus-naïve participants (17). In this study, the authors found that the primary ZIKV group
315 did not have higher viremia or pro-inflammatory cytokines than the DENV group, leading them
316 to propose that the mechanism of enhanced severity may differ from classical ADE. Collectively,
317 these observations suggest that induction of primary ZIKV immunity may increase risk of future
318 dengue disease, posing a potential challenge to development of Zika vaccines.

319

320 Our study also shows that the order of sequential DENV and ZIKV infections modulates future

321 disease outcome. DENV followed by ZIKV infection increased the risk of a symptomatic and
322 severe DENV infection, whereas ZIKV followed by DENV infection did not. When stratified by
323 incoming serotype, we found that DENV-ZIKV infection histories increased the risk only for
324 DENV2 and DENV4, again showing immunological similarities in secondary DENV infections
325 by these two viruses. A study in macaques has similarly found that DENV-ZIKV sequence
326 produced an inferior immune response compared to ZIKV-DENV exposed monkeys, impacting
327 the quality of antibodies produced in response to tertiary DENV infection and the magnitude of
328 recall memory immune response, suggesting important differences by sequential order of
329 infection (19, 29, 30). Notably, a study in Sri Lanka showed that individuals with prior DENV
330 and ZIKV infection histories or only prior DENV infection experience increased risk of plasma
331 leakage, shock, and severe dengue compared to flavivirus-naïve individuals, although order of
332 infections could not be determined (31).

333
334 Interestingly, we found that having had two prior DENV infections was a significant risk factor
335 for subsequent symptomatic and severe DENV infections as well as DENV3 symptomatic
336 infection. However, we did not observe increased disease risk in groups with at least two prior
337 DENV infections, with or without subsequent ZIKV infection (2+DENV and 2+DENV-ZIKV),
338 and protective effects were observed for the 2+DENV group against any dengue case and
339 symptomatic DENV1 infection. These groups include some individuals who entered the study
340 with detectable anti-DENV antibodies and then experienced at least one DENV infection,
341 meaning that some may have had only two prior infections. One interpretation of these findings
342 is that there is something distinct about the DENV-DENV group, which constitutes a small
343 fraction of the overall cohort. They may be at higher risk for exposure, although our

344 neighborhood level analyses did not support this hypothesis. Alternatively, these findings may
345 suggest that two DENV infections are not always be enough to provide broad protection against
346 symptomatic DENV infection. Prior work has suggested that tertiary infections are rare in
347 hospital settings (32, 33). Here we report mild-to-severe tertiary infections, as our community-
348 based cohort allowed us to capture a greater spectrum of the disease. Our results are consistent
349 with prior reports from the Pediatric Dengue Cohort Study that tertiary infections for some
350 epidemic years were more likely to be symptomatic than inapparent (34). Although we
351 previously found that having two or more DENV infections protected against DENV2 cases
352 during the 2019-2020 epidemic, DENV2 had circulated in the years before that epidemic,
353 implying that one of the prior infections may have been with DENV2 and thus that homotypic
354 immunity contributed to reduced risk (35, 36). In contrast, DENV1 and DENV3 have not
355 circulated appreciably in Nicaragua for more than 10 years, and our pediatric study population
356 had never experienced a large DENV4 epidemic. Lack of homotypic immunity against these
357 serotypes and insufficient heterotypic immunity may have driven the explosive dengue epidemic
358 in 2022-2023 and explained the lack of protection even in those with two prior DENV infections.
359
360 Our findings also support the previous observation that pre-existing DENV immunity
361 differentially modulates subsequent symptomatic and severe disease depending on infecting
362 serotype. We previously showed that low-to-intermediate pre-existing DENV iELISA antibody
363 titers were associated with increased symptomatic and severe DENV2 and DENV3 disease,
364 whereas high titers were protective against DENV1 and DENV3 (26). Here, we found that a
365 history of any flavivirus infection increased the risk of future DwWS/SD and DHF/DSS as well
366 as dengue cases caused by DENV2 and DENV4, but was protective against DENV1 and had

367 neutral risk against DENV3. Low-to-intermediate pre-existing antibody titers increased risk of
368 DENV2 and DENV4 infections compared to flavivirus-naïve individuals, and high titers were
369 not associated with increased risk nor protection. In contrast, high pre-existing antibodies
370 reduced risk of symptomatic DENV1 and DENV3 infections, while low titers were associated
371 with increased risk of symptomatic DENV3 infection. Structural differences between the viruses
372 may explain a lower probability of ADE with DENV1, which is associated with lower frequency
373 of symptomatic and severe secondary infections (37). DENV1 has been shown to produce more
374 mature viral particles *in vivo*, which are poorly neutralized by fusion loop antibodies, and it has
375 been shown *in vitro* that some DENV1 particles breathe less compared to other serotypes (38,
376 39).

377
378 We also showed that anti-DENV antibodies help mediate the relationship between DENV or
379 ZIKV infection and risk of subsequent symptomatic DENV infection via antibodies. Across
380 infection histories, we found that DENV iELISA antibody titers are good predictors of disease
381 outcome. This observation is consistent with previous studies showing that high anti-DENV
382 antibody titers are good correlates of protection following vaccination with dengue candidate
383 CYD-TDV, while a lower titer was a correlate of risk (40). Notably, some infection histories still
384 retain direct effects, suggesting that there are differences in the quality of immunity that are not
385 fully captured by our measure of anti-DENV antibodies.

386
387 Prior work has suggested that cross-reactive protection against DENV wanes within one to three
388 years post-infection, and a longer time between sequential DENV infections increases the
389 probability of symptomatic DENV infections (32, 34, 41, 42). Our previous work showed that

390 cross-reactive antibodies after a primary DENV infection are stable by about 6 months, while
391 primary ZIKV infection elicits cross-reactive DENV antibodies that increased over time up to
392 three years (28). In contrast, after secondary DENV or DENV-ZIKV infection, we observed
393 high antibodies followed by long-term decay. Here, we show that after 3 years, DENV cross-
394 reactive antibodies in primary ZIKV participants begin to decay. We also showed that the ZIKV-
395 DENV group elicited slightly higher DENV iELISA titer than the DENV-ZIKV group did,
396 suggesting broader immunity, which could have resulted in a reduction of risk for a subsequent
397 symptomatic DENV infection. However, the ZIKV-DENV group experienced rapid antibody
398 decay, raising the possibility that the protective effect may not be long-lived.

399
400 Our study has several strengths, including a robust study design that has been sustained over 19
401 years. This extensive period of observation has enabled us to detect epidemics of all DENV
402 serotypes and ZIKV, encompassing the entire spectrum of disease severity, from inapparent to
403 symptomatic and severe infections. This comprehensive dataset allows the capture of detailed
404 arboviral infection histories, including single and sequential DENV and ZIKV infections, with a
405 large sample size. Nonetheless, our study has several limitations. The data is derived from a
406 Nicaraguan cohort, and the results may not generalize to other settings with different DENV and
407 ZIKV strains as well as other circulating flaviviruses. However, given the similarity in dengue
408 epidemiology across the Americas, our findings will likely have broader applicability in the
409 region (43-45). Additionally, the exact sequence of infecting DENV serotypes is not recorded
410 due to a lack of serotype information of inapparent infections. The sequence of infecting DENV
411 serotypes may modulate disease outcome in ways we could not account for here. Further, risk
412 calculations using all Pediatric Dengue Cohort Study participants in the denominator assumes

413 risk is homogenous, which is implausible. To account for this, we adjusted results by prior year
414 DENV seroprevalence at the neighborhood levels as a proxy for spatial risk and showed that our
415 results did not qualitatively change. Finally, our mediation analysis should not be interpreted
416 causally as it relies on diverse assumptions that cannot be fully satisfied using our study design.

417

418 In summary, this study highlights the serotype-specific modulation of infection risk based on
419 prior flavivirus exposure. The observation that individuals with prior ZIKV, DENV, or DENV-
420 ZIKV infections were at increased risk of symptomatic dengue caused by multiple DENV
421 serotypes suggests that ADE potential is not limited to DENV2 but also extends DENV3 and
422 DENV4. The findings presented here, in conjunction with other studies, suggest that the
423 introduction of a monovalent ZIKV vaccine that induces immunity similar to natural ZIKV
424 infection could have a negative effect on dengue outcome if introduced to DENV-naïve
425 populations. These findings advocate a more nuanced and integrative approach to vaccine
426 deployment strategies, considering the history of flavivirus infections and the level of flavivirus
427 immunity in the target population. Further, our results suggest that introducing ZIKV vaccines is
428 unlikely to broaden protective immunity in individuals with one prior DENV infection, and if
429 anything, may increase future dengue risk. Our findings also suggest that some individuals with
430 two natural DENV infections remain at risk of DwWS/SD and may suggest that even some
431 individuals who are DENV immune before receiving dengue vaccines may remain at heightened
432 risk for disease. The possibility that vaccine-induced immunity could inadvertently elevate the
433 risk of severe disease warrants an evidence-based approach to vaccination programs and longer-
434 term follow-up times to evaluate protection against all DENV serotypes.

435

436

437 **MATERIALS AND METHODS**

438 *Study design*

439 This study aimed to assess how pre-existing ZIKV and DENV immunity impacts the risk of
440 symptomatic DENV1-4 and severe dengue disease, at a population level. To do this, we analyzed
441 serological data collected since 2004 from a continuous observational cohort study in Nicaragua,
442 adhering to the guidelines in the Strengthening the Reporting of Observational Studies in
443 Epidemiology checklist. This study did not involve any form of randomization or blinding
444 measures. Our analysis included all individuals, with results reported only for those with DENV
445 and ZIKV infection histories that could be clearly determined. All relevant data available during
446 the manuscript preparation was included. The primary endpoint was the risk of symptomatic
447 DENV infection influenced by previous ZIKV or DENV immunity and the infecting DENV
448 serotype. Secondary endpoints were the impact of pre-existing antibody titers on dengue and
449 severe dengue risk, as well as antibody magnitude and long-term kinetics following exposure to
450 one or multiple flaviviruses.

451

452 *Ethics statement*

453 The human subjects protocol of the Pediatric Dengue Cohort Study was reviewed and approved
454 by the Institutional Review Boards of the University of California, Berkeley (2010-09-2245), the
455 University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health (CIRE-
456 09/03/07-008). Parents or legal guardians of all subjects provided written informed consent, and
457 participants aged 6 years of age and older provided assent.

458

459 *The Pediatric Dengue Cohort Study*

460 The Pediatric Dengue Cohort Study is an ongoing prospective study that began in 2004 and is
461 conducted at the Sócrates Flores Vivas Health Center (HCSFV), based in District 2 of Managua,
462 Nicaragua (46). This district is adjacent to Lake Managua and consists of neighborhoods ranging
463 from low to middle socioeconomic status (SES). The HCSFV serves approximately 62,000
464 residents across 18 neighborhoods within District 2 (47). The illiteracy rate in this area is
465 approximately 7%, and over 90% of the households have access to running water and a sewage
466 system. The streets are largely paved, and all residents have access to electricity (48).

467
468 The study tracks approximately 4,000 active participants yearly and has followed 9,800 children
469 since its inception. To maintain the original age distribution of the cohort, ~300 two-year-olds,
470 along with some children aged 3-11 years, are enrolled in the study each year. The age limit of
471 the study was increased to 15, 16, and 17 years in 2018, 2019, and 2022, respectively.
472 Participants are provided free medical care 24 hours per day, 365 days per year, through study
473 physicians at the HCSFV. If a child requires hospitalization, they are transferred by study staff to
474 the study hospital, the National Pediatric Reference Hospital (Hospital Infantil Manuel de Jesús
475 Rivera). Children presenting with fever and since July 2016, rash, are screened for signs and
476 symptoms of dengue, Zika, and chikungunya. Symptomatic infections are captured through
477 passive surveillance, enhanced with periodic home visits. Acute (0-5 days post symptoms onset)
478 and convalescent samples (14-21 days) are collected for each suspected case to confirm infection
479 (35). Every year in March-April (previously in July before 2011), healthy blood samples are
480 provided by all participants to evaluate inapparent arboviral infections (35).

481

482 *Case definitions*

483 Upon medical examination, children are categorized into A, B, C, or D cases, as follows: **A**:
484 those meeting the 1997 or 2009 World Health Organization (WHO) criteria for dengue; **B**: those
485 with undifferentiated fever of undefined origin; **C**: those with an acute febrile illness identified as
486 a disease other than dengue, chikungunya, or Zika; **D**: those with other conditions (including
487 rash) that do not include a fever. A range of clinical and laboratory information is collected for
488 each participant, covering 189 different variables (35), including vital signs, temperature,
489 musculoskeletal pain, respiratory symptoms, gastrointestinal symptoms, indicators of
490 dehydration, rashes, and other skin anomalies. Since 2004, all cases falling into categories A and
491 B are tested for acute DENV infection and, starting in 2014, also for chikungunya virus
492 (CHIKV). As of 2016, all cases meeting the definitions of A, B, or D (rash without fever) are
493 tested for acute DENV, CHIKV, and ZIKV infection.

494

495 **Detection of cases:** Acute samples are examined using the ZCD multiplex real-time reverse
496 transcriptase PCR (rRT-PCR) assay for DENV, ZIKV, and CHIKV (49); prior to the
497 introduction of ZIKV into the cohort, other RT-PCR methods were used (50-52). DENV-positive
498 samples are further analyzed by rRT-PCR to determine the infecting DENV serotype, and a
499 subset undergo virus isolation in C6/36 cells (50, 53). Paired acute-phase (days 1-5) and
500 convalescent-phase (days 14-21) samples are evaluated for seroconversion of IgM antibodies, an
501 indicator of a recent infection, using separate in-house DENV and ZIKV IgM capture (MAC)-
502 ELISAs (54, 55). DENV inhibition ELISA (iELISA) and ZIKV iELISA assays are used to
503 measure total anti-DENV and -ZIKV antibodies, respectively, and to detect seroconversion or a
504 4-fold or greater increase in antibodies (12, 54). For arbovirus cases from 2016-2017, we also

505 used a computer algorithm to help identify Zika cases from dengue cases based on the results of
506 the aforementioned antibody tests (56).

507
508 **Detection of inapparent infections:** To detect inapparent DENV infections, before 2016, we
509 identified an inapparent DENV infection if a seroconversion or a ≥ 4 -fold increase in antibody
510 titer was recorded between annual samples as measured by DENV iELISA, provided no
511 observed febrile episode was identified as a dengue case (12). After the 2016 Zika epidemic, we
512 defined inapparent DENV infections as seroconversion or a ≥ 4 -fold rise in DENV iELISA titer
513 without seroconversion by ZIKV NS1 BOB ELISA, seroconversion or a ≥ 4 -fold rise by ZIKV
514 iELISA, or an observed dengue, Zika, or flavivirus case in that year (54). Inapparent flavivirus
515 (DENV or ZIKV without ascertainment) infections were defined by seroconversion or a ≥ 4 -fold
516 rise by both DENV iELISA and ZIKV iELISA, no seroconversion by ZIKV NS1 BOB ELISA,
517 and no documented dengue, Zika, or flavivirus case in that year. Seroconversion by ZIKV NS1
518 BOB ELISA and/or seroconversion or ≥ 4 -fold rise by ZIKV iELISA was used to detect
519 inapparent ZIKV infections.

520
521 *Infection histories*
522 The study participants were grouped into categories based on their DENV and/or ZIKV infection
523 history. When a child experienced another infection, they were moved to the group that reflected
524 their new infection status. We note that none of the groups with ZIKV existed before the major
525 Zika epidemic in 2016. The different groups included children who: were free from DENV (from
526 2004-2015) or ZIKV (from 2016-2023) immunity at the start of the study and did not experience
527 a DENV, ZIKV, or flavivirus infection during the study period (**flavivirus-naïve**); entered the

528 study with DENV immunity, determined using the DENV iELISA (titer $\geq 1:10$) and with no
529 antibody titers as measured in other assays or with low ZIKV titers and no subsequent detected
530 infection (**DENV-immune**); were initially free from flaviviruses but were observed to have
531 experienced precisely one DENV infection (**DENV**); were initially free from flaviviruses but
532 who experienced exactly two documented DENV infections (**DENV-DENV**). Since 2020, ZIKV
533 titers were disregarded for new enrollees, given that most new enrollees did not experience the
534 ZIKV epidemic, given their age, and there is no evidence that ZIKV has circulated after 2017.
535 Other groups included children who: either entered the study without flavivirus immunity and
536 experienced more than two documented DENV infections or who entered the study with
537 flavivirus immunity and had one or more observed DENV infection (**2+DENV**); experienced
538 only one prior ZIKV infection (**ZIKV**) – these children either entered the study without
539 flavivirus immunity and had one observed ZIKV infection or a flavivirus infection (see
540 definition above; based on the epidemiology at the time, these are most likely ZIKV infections),
541 or positive for ZIKV but with low DENV titers. The **DENV-ZIKV** group included children who
542 experienced one DENV infection followed by one ZIKV infection; the **2+DENV-ZIKV** group
543 included children with two or more prior DENV infections followed by one ZIKV infection; and
544 the **ZIKV-DENV** group comprised children with a primary ZIKV infection followed by one
545 DENV infection. The ZIKV-DENV group did not exist prior to the DENV2 epidemic in 2019.
546 Other infection histories included children who had a ZIKV-DENV infection history who
547 subsequently experienced another DENV infection (**ZIKV-DENV-DENV**); this group (N = 15)
548 experienced no subsequent DENV infections and was not included in our analyses of infection
549 histories, but they were included in the titer analyses. The **DENV-ZIKV-2+DENV** group
550 consisted of participants who initially had a DENV-ZIKV-DENV infection history and later

551 experienced another DENV infection. This group (N = 3) experienced no subsequent DENV
552 infections and was not included in our analyses of infection histories, but they were included in
553 the titer analyses. Finally, the **2+DENV-ZIKV-DENV** group consisted of participants who
554 initially were in the 2+DENV group and later had one ZIKV and other DENV infection. Again,
555 this group (N = 11) had no further infections and was not included in our analyses of infection
556 histories but was included in the titer analyses. Some children with ZIKV infections in 2016-
557 2017 were observed to have increasing titers in DENV and ZIKV serological assays for multiple
558 years. These infections were not considered actual infections and were therefore excluded when
559 defining infection histories.

560

561 *Severity classification*

562 Dengue cases in the study were classified according to the World Health Organization's (WHO)
563 guidelines from 1997 and 2009. According to the 1997 WHO case classification, Dengue Fever
564 (DF) was defined as a febrile case with at least two of the following symptoms: headache,
565 arthralgia, retro-orbital pain, rash, myalgia, hemorrhagic manifestations, and leukopenia. Dengue
566 Hemorrhagic Fever (**DHF**) was defined as a laboratory-confirmed dengue case presenting with:
567 1) fever or a history of fever; 2) hemorrhagic manifestations; 3) thrombocytopenia ($\leq 100,000$
568 platelets/ml); and 4) signs of plasma leakage. The criteria for plasma leakage included age and
569 sex-specific elevated hematocrit levels, $\geq 20\%$ hemoconcentration, pleural effusion, ascites,
570 edema, hypoproteinemia, hypoalbuminemia, or other evidence of plasma leak. Dengue Shock
571 Syndrome (**DSS**) is a DHF case with signs of circulatory failure, including 1) hypotension for the
572 patient's age or a narrow pulse pressure (< 20 mm Hg), and 2) clinical signs of shock such as a
573 rapid, weak pulse, cold and clammy skin, or poor capillary refill.

574

575 According to the 2009 WHO case classification, Dengue with Warning Signs (DwWS) was used
576 when a laboratory-confirmed case presented with symptoms such as abdominal pain, persistent
577 vomiting, fluid accumulation, lethargy, mucosal bleeding, liver enlargement, or a rise in
578 hematocrit concurrent with a decrease in platelet count. Severe Dengue (SD) indicated
579 laboratory-confirmed cases with severe bleeding, significant plasma leakage leading to shock,
580 fluid accumulation resulting in respiratory distress, or organ failure. Organ involvement was
581 signified by liver ALT or AST levels of $\geq 1,000$, impaired consciousness, or heart or other organ
582 failures.

583

584

585 *Inclusion criteria for cases in the 2022 epidemic cases*

586 Between March 19, 2022, and July 2, 2023, we documented 384 dengue cases. Notably, 15 of
587 these cases were identified based on DENV serology, but they also exhibited cross-reactivity
588 with ZIKV serology. Because ZIKV has not been detected since its initial introduction in the
589 region in 2016, these cases were classified as DENV cases in the present study. We excluded 10
590 cases that had a second-laboratory-confirmed DENV infection in the same epidemic, including 8
591 where both infections were confirmed by RT-PCR, and 2 where one of the infections was
592 confirmed by DENV serology. Our analysis ultimately utilized 374 total cases, including 39
593 identified through DENV serology.

594

595 *Statistical analyses*

596 All statistical and epidemiological analyses were conducted using R (R Foundation for Statistical

597 Computing, version 4.5.0) and used lme4, segmented, and mediation packages (57-60). Log-
598 binomial and log-poisson generalized linear regression models (GLMs) were used to estimate the
599 risk of any dengue case given infection history. Log-poisson GLMs were used when log-
600 binomial models would not converge due to rare disease outcomes; that is, in instances where we
601 had low numbers of dengue cases. Models were adjusted for age, sex, and time since last
602 infection. All analyses were also performed separately for each infecting DENV serotype. We
603 were unable to analyze DENV serotype in analyses of DENV severity due to sample size
604 limitations. We calculated 95% confidence intervals (CIs) of the predicted values based on the
605 standard errors (SE), assuming a normal distribution (predicted mean plus or minus ± 1.96
606 multiplied by the SE). GLMs were used for all 2022-2023 epidemic analyses since each
607 participant contributed only one year to the data.

608 For analyses using all 19 years of cohort data, generalized linear mixed models (GLMMs) were
609 used to incorporate random effects, allowing us to account for repeated measurements by
610 clustering at the individual level (longitudinal data analysis). We performed two main analyses:
611 one that studied the effect of infection histories on DENV outcomes, and one that categorized
612 participants as flavivirus-naïve versus those exposed to any number of DENV or ZIKV
613 infections (flavi-immune). Additionally, we adjusted for age, sex, time since last infection, and
614 cohort epidemic year. Neighborhood seroprevalence was also included as a proxy for exposure in
615 sensitivity analyses. Log-binomial and log-poisson GLMMs were used to model the relationship
616 between pre-existing DENV iELISA titers and disease outcome. These models were also
617 adjusted for age, sex, time since the last infection and cohort epidemic year.

618

619 Mediation analysis was used to differentiate the direct versus indirect effect of antibody titers in

620 explaining the relationship between infection history and disease presentation for the 2022-2023
621 epidemic. Using logistic regression models, adjusting for age, sex, and year, we first regressed
622 the relationship between infection history and DENV iELISA titers and then we modeled the
623 likelihood of being a DENV case as a function of infection history and DENV iELISA titers. We
624 used non-parametric bootstrapping and bias-corrected, accelerated confidence intervals
625 employing 1,000 simulations. The indirect effects were calculated as the expected difference in
626 the potential outcomes if DENV iELISA titers were within a specific range versus outside of that
627 range. We performed separate analyses comparing titers of 10-320 vs. higher or lower and >320
628 vs. ≤ 320 . We performed pairwise comparisons of flavivirus-naïve vs non-flavivirus-naïve
629 categories (DENV immune, DENV, ZIKV, DENV-DENV, DENV-ZIKV, ZIKV-DENV,
630 2+DENV, 2+DENV-ZIKV) resulting in eight comparisons or contrasts. The proportion of
631 mediation was determined by dividing the indirect effect by the total effect. When a mediation
632 model was inconsistent, meaning that the direct and indirect effects were in opposite signs, the
633 absolute value of them were used to calculate the mediation contribution proportion (61).

634
635 We measured antibody dynamics by infection history group using Gaussian generalized additive
636 mixed models (GAMMs) that included random effects for both the intercept and slope, as each
637 individual had a different starting titer magnitude and titer kinetics. Antibody dynamics analyses
638 were adjusted for age and sex. For computational efficiency purposes, in order to account for the
639 individual variability, all continuous covariates were discretized, including time since last
640 infection (but allowing time since last infection to be smooth) and variance parameters were
641 estimated using a fast restricted maximum likelihood (REML) function (62). We used these
642 models to identify relevant inflection points in the antibody kinetics for further analyses related

643 to intercepts and slopes within each infection history group. Multiphasic linear models were then
644 used to model the various phases of antibody decay or rise while estimating antibody half-lives.
645 Half-lives were calculated by dividing $\log(2)$ titers by the slope. A positive half-life indicated
646 that antibody titers waned, whereas a negative-half-life represented increasing antibody titers.

647

648 **References and Notes**

- 649 1. S. Leta, T. J. Beyene, E. M. De Clercq, K. Amenu, M. U. G. Kraemer, C. W. Revie,
650 Global risk mapping for major diseases transmitted by *Aedes aegypti* and *Aedes*
651 *albopictus*. *Int. J. Infect. Dis.* **67**, 25-35 (2018).
- 652 2. L. Cattarino, I. Rodriguez-Barraquer, N. Imai, D. A. T. Cummings, N. M. Ferguson,
653 Mapping global variation in dengue transmission intensity. *Sci. Transl. Med.* **12**,
654 eaax4144 (2020).
- 655 3. N. R. Faria, J. Quick, I. M. Claro, J. Theze, J. G. de Jesus, M. Giovanetti, M. U. G.
656 Kraemer, S. C. Hill, A. Black, A. C. da Costa, L. C. Franco, S. P. Silva, C. H. Wu, J.
657 Raghwani, S. Cauchemez, L. du Plessis, M. P. Verotti, W. K. de Oliveira, E. H. Carmo,
658 G. E. Coelho, Acfs Santelli, L. C. Vinhal, C. M. Henriques, J. T. Simpson, M. Loose, K.
659 G. Andersen, N. D. Grubaugh, S. Somasekar, C. Y. Chiu, J. E. Munoz-Medina, C. R.
660 Gonzalez-Bonilla, C. F. Arias, L. L. Lewis-Ximenez, S. A. Baylis, A. O. Chieppe, S. F.
661 Aguiar, C. A. Fernandes, P. S. Lemos, B. L. S. Nascimento, H. A. O. Monteiro, I. C.
662 Siqueira, M. G. de Queiroz, T. R. de Souza, J. F. Bezerra, M. R. Lemos, G. F. Pereira, D.
663 Loudal, L. C. Moura, R. Dhaliya, R. F. Franca, T. Magalhaes, E. T. Marques, Jr., T.
664 Jaenisch, G. L. Wallau, M. C. de Lima, V. Nascimento, E. M. de Cerqueira, M. M. de
665 Lima, D. L. Mascarenhas, J. P. M. Neto, A. S. Levin, T. R. Tozetto-Mendoza, S. N.
666 Fonseca, M. C. Mendes-Correa, F. P. Milagres, A. Segurado, E. C. Holmes, A. Rambaut,
667 T. Bedford, M. R. T. Nunes, E. C. Sabino, L. C. J. Alcantara, N. J. Loman, O. G. Pybus,
668 Establishment and cryptic transmission of Zika virus in Brazil and the Americas. *Nature*
669 **546**, 406-410 (2017).
- 670 4. A. E. Ngonu, S. Shresta, Immune Response to Dengue and Zika. *Annu. Rev. Immunol.*

- 671 **36**, 279-308 (2018).
- 672 5. L. C. Katzelnick, S. Bos, E. Harris, Protective and enhancing interactions among dengue
673 viruses 1-4 and Zika virus. *Curr. Opin. Virol.* **43**, 59-70 (2020).
- 674 6. E. N. Gallichotte, R. S. Baric, A. M. de Silva, The Molecular Specificity of the Human
675 Antibody Response to Dengue Virus Infections. *Adv. Exp. Med. Biol.* **1062**, 63-76
676 (2018).
- 677 7. L. C. Katzelnick, M. Montoya, L. Gresh, A. Balmaseda, E. Harris, Neutralizing antibody
678 titers against dengue virus correlate with protection from symptomatic infection in a
679 longitudinal cohort. *Proc. Natl. Acad. Sci. U S A* **113**, 728-733 (2016).
- 680 8. S. Bos, A. L. Graber, J. A. Cardona-Ospina, E. M. Duarte, J. V. Zambrana, J. A. Ruiz
681 Salinas, R. Mercado-Hernandez, T. Singh, L. C. Katzelnick, A. de Silva, G. Kuan, A.
682 Balmaseda, E. Harris, The association of neutralizing antibodies with protection against
683 symptomatic dengue virus infection varies by serotype, prior infection history, and assay
684 condition. *medRxiv*, Preprint at: <https://doi.org/10.1101/2023.06.20.23291522> (2023).
- 685 9. D. Buddhari, J. Aldstadt, T. P. Endy, A. Srikiatkachorn, B. Thaisomboonsuk, C.
686 Klungthong, A. Nisalak, B. Khuntirat, R. G. Jarman, S. Fernandez, S. J. Thomas, T. W.
687 Scott, A. L. Rothman, I. K. Yoon, Dengue virus neutralizing antibody levels associated
688 with protection from infection in thai cluster studies. *PLoS Negl. Trop. Dis.* **8**, e3230
689 (2014).
- 690 10. A. Nisalak, H. E. Clapham, S. Kalayanaroj, C. Klungthong, B. Thaisomboonsuk, S.
691 Fernandez, J. Reiser, A. Srikiatkachorn, L. R. Macareo, J. T. Lessler, D. A. Cummings,
692 I. K. Yoon, Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in
693 Bangkok, Thailand, 1973-2012. *Am. J. Trop. Med. Hyg.* **94**, 1342-1347 (2016).

- 694 11. N. Sangkawibha, S. Rojanasuphot, S. Ahandrik, S. Viriyapongse, S. Jatanasen, V. Salitul,
695 B. Phanthumachinda, S. B. Halstead, Risk factors in dengue shock syndrome: a
696 prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. *Am. J.*
697 *Epidemiol.* **120**, 653-669 (1984).
- 698 12. L. C. Katzelnick, L. Gresh, M. E. Halloran, J. C. Mercado, G. Kuan, A. Gordon, A.
699 Balmaseda, E. Harris, Antibody-dependent enhancement of severe dengue disease in
700 humans. *Science* **358**, 929-932 (2017).
- 701 13. H. Salje, D. A. T. Cummings, I. Rodriguez-Barraquer, L. C. Katzelnick, J. Lessler, C.
702 Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo, I. K.
703 Yoon, R. Jarman, S. Thomas, A. L. Rothman, T. Endy, S. Cauchemez, Reconstruction of
704 antibody dynamics and infection histories to evaluate dengue risk. *Nature* **557**, 719-723
705 (2018).
- 706 14. S. B. Halstead, S. Nimmannitya, S. N. Cohen, Observations related to pathogenesis of
707 dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and
708 virus recovered. *Yale. J. Biol. Med.* **42**, 311-328 (1970).
- 709 15. S. B. Halstead, E. J. O'Rourke, Dengue viruses and mononuclear phagocytes. I. Infection
710 enhancement by non-neutralizing antibody. *J. Exp. Med.* **146**, 201-217 (1977).
- 711 16. M. G. Guzman, M. Alvarez, S. B. Halstead, Secondary infection as a risk factor for
712 dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of
713 antibody-dependent enhancement of infection. *Arch. Virol.* **158**, 1445-1459 (2013).
- 714 17. C. F. Estofolete, A. F. Versiani, F. S. Dourado, Bhga Milhim, C. C. Pacca, G. C. D. Silva,
715 N. Zini, B. F. D. Santos, F. A. Gandolfi, N. F. B. Mistrão, P. H. C. Garcia, R. S. Rocha,
716 L. Gehrke, I. Bosch, R. E. Marques, M. M. Teixeira, F. G. da Fonseca, N. Vasilakis, M.

- 717 L. Nogueira, Influence of previous Zika virus infection on acute dengue episode. *PLoS*
718 *Negl. Trop. Dis.* **17**, e0011710 (2023).
- 719 18. Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O,
720 Elizondo D, Miranda T, Bustos Carillo F, Mercado JC, Latta K, Schiller A, Segovia-
721 Chumbez B, Ojeda S, Sanchez N, Plazaola M, Coloma J, Halloran ME, Premkumar L,
722 Gordon A, Narvaez F, de Silva AM, Kuan G, Balmaseda A, Harris E, Zika virus
723 infection enhances future risk of severe dengue disease. *Science (New York, N.Y.)* **369**,
724 1123-1128 (2020).
- 725 19. M. E. Breitbach, C. M. Newman, D. M. Dudley, L. M. Stewart, M. T. Aliota, M. R.
726 Koenig, P. M. Shepherd, K. Yamamoto, C. M. Crooks, G. Young, M. R. Semler, A. M.
727 Weiler, G. L. Barry, H. Heimsath, E. L. Mohr, J. Eichkoff, W. Newton, E. Peterson, N.
728 Schultz-Darken, S. R. Permar, H. Dean, S. Capuano, 3rd, J. E. Osorio, T. C. Friedrich, D.
729 H. O'Connor, Primary infection with dengue or Zika virus does not affect the severity of
730 heterologous secondary infection in macaques. *PLoS Pathog.* **15**, e1007766 (2019).
- 731 20. J. George, W. G. Valiant, M. J. Mattapallil, M. Walker, Y. S. Huang, D. L.
732 Vanlandingham, J. Misamore, J. Greenhouse, D. E. Weiss, D. Verthelyi, S. Higgs, H.
733 Andersen, M. G. Lewis, J. J. Mattapallil, Prior Exposure to Zika Virus Significantly
734 Enhances Peak Dengue-2 Viremia in Rhesus Macaques. *Sci Rep* **7**, 10498 (2017).
- 735 21. M. G. Guzman, G. Kouri, L. Valdes, J. Bravo, M. Alvarez, S. Vazques, I. Delgado, S. B.
736 Halstead, Epidemiologic studies on Dengue in Santiago de Cuba, 1997. *Am. J. Epidemiol.*
737 **152**, 793-799 (2000).
- 738 22. I. Y. Amaya-Larios, R. A. Martinez-Vega, F. A. Diaz-Quijano, E. Sarti, E. Puentes-
739 Rosas, L. Chihu, J. Ramos-Castaneda, Risk of dengue virus infection according to

- 740 serostatus in individuals from dengue endemic areas of Mexico. *Sci Rep* **10**, 19017
741 (2020).
- 742 23. S. Henein, J. Swanstrom, A. M. Byers, J. M. Moser, S. F. Shaik, M. Bonaparte, N.
743 Jackson, B. Guy, R. Baric, A. M. de Silva, Dissecting Antibodies Induced by a Chimeric
744 Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in
745 Naive and Dengue-Exposed Individuals. *J. Infect. Dis.* **215**, 351-358 (2017).
- 746 24. E. Harris, E. Videia, L. Perez, E. Sandoval, Y. Tellez, M. L. Perez, R. Cuadra, J. Rocha,
747 W. Idiaquez, R. E. Alonso, M. A. Delgado, L. A. Campo, F. Acevedo, A. Gonzalez, J. J.
748 Amador, A. Balmaseda, Clinical, epidemiologic, and virologic features of dengue in the
749 1998 epidemic in Nicaragua. *Am. J. Trop. Med. Hyg.* **63**, 5-11 (2000).
- 750 25. Z. Moodie, M. Juraska, Y. Huang, Y. Zhuang, Y. Fong, L. N. Carpp, S. G. Self, L.
751 Chambonneau, R. Small, N. Jackson, F. Noriega, P. B. Gilbert, Neutralizing Antibody
752 Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin
753 America. *J. Infect. Dis.* **217**, 742-753 (2018).
- 754 26. L. C. Katzelnick, C. Narvaez, S. Arguello, B. Lopez Mercado, D. Collado, O. Ampie, D.
755 Elizondo, T. Miranda, F. Bustos Carillo, J. C. Mercado, K. Latta, A. Schiller, B. Segovia-
756 Chumbez, S. Ojeda, N. Sanchez, M. Plazaola, J. Coloma, M. E. Halloran, L. Premkumar,
757 A. Gordon, F. Narvaez, A. M. de Silva, G. Kuan, A. Balmaseda, E. Harris, Zika virus
758 infection enhances future risk of severe dengue disease. *Science* **369**, 1123-1128 (2020).
- 759 27. S. Olkowski, B. M. Forshey, A. C. Morrison, C. Rocha, S. Vilcarromero, E. S. Halsey, T.
760 J. Kochel, T. W. Scott, S. T. Stoddard, Reduced risk of disease during postsecondary
761 dengue virus infections. *J. Infect. Dis.* **208**, 1026-1033 (2013).
- 762 28. L. C. Katzelnick, J. V. Zambrana, D. Elizondo, D. Collado, N. Garcia, S. Arguello, J. C.

- 763 Mercado, T. Miranda, O. Ampie, B. L. Mercado, C. Narvaez, L. Gresh, R. A. Binder, S.
764 Ojeda, N. Sanchez, M. Plazaola, K. Latta, A. Schiller, J. Coloma, F. B. Carrillo, F.
765 Narvaez, M. E. Halloran, A. Gordon, G. Kuan, A. Balmaseda, E. Harris, Dengue and
766 Zika virus infections in children elicit cross-reactive protective and enhancing antibodies
767 that persist long term. *Sci. Transl. Med.* **13**, eabg9478 (2021).
- 768 29. Pérez-Guzmán EX, Pantoja P, Serrano-Collazo C, Hassert MA, Ortiz-Rosa A, Rodríguez
769 IV, Giavedoni L, Hodara V, Parodi L, Cruz L, Arana T, White LJ, Martínez MI,
770 Weiskopf D, Brien JD, de Silva A, Pinto AK, Sariol CA, Time elapsed between Zika and
771 dengue virus infections affects antibody and T cell responses. *Nat. comm.* **10**, (2019).
- 772 30. N. Marzan-Rivera, C. Serrano-Collazo, L. Cruz, P. Pantoja, A. Ortiz-Rosa, T. Arana, M.
773 I. Martinez, A. G. Burgos, C. Roman, L. B. Mendez, E. Geerling, A. K. Pinto, J. D.
774 Brien, C. A. Sariol, Infection order outweighs the role of CD4(+) T cells in tertiary
775 flavivirus exposure. *iScience* **25**, 104764 (2022).
- 776 31. B. M. Valencia, P. C. Sigera, P. Weeratunga, N. Tedla, D. Fernando, S. Rajapakse, A. R.
777 Lloyd, C. Rodrigo, Effect of prior Zika and dengue virus exposure on the severity of a
778 subsequent dengue infection in adults. *Sci. Rep.* **12**, 17225 (2022).
- 779 32. P. Bhooniboonchoo, A. Nisalak, N. Chansatiporn, I. K. Yoon, S. Kalayanaroj, M.
780 Thipayamongkolgul, T. Endy, A. L. Rothman, S. Green, A. Srikiatkachorn, D.
781 Buddhari, M. P. Mammen, R. V. Gibbons, Sequential dengue virus infections detected in
782 active and passive surveillance programs in Thailand, 1994-2010. *BMC Public Health* **15**,
783 250 (2015).
- 784 33. R. V. Gibbons, S. Kalanaroj, R. G. Jarman, A. Nisalak, D. W. Vaughn, T. P. Endy, M.
785 P. Mammen, Jr., A. Srikiatkachorn, Analysis of repeat hospital admissions for dengue to

- 786 estimate the frequency of third or fourth dengue infections resulting in admissions and
787 dengue hemorrhagic fever, and serotype sequences. *Am. J. Trop. Med. Hyg.* **77**, 910-913
788 (2007).
- 789 34. M. Montoya, L. Gresh, J. C. Mercado, K. L. Williams, M. J. Vargas, G. Gutierrez, G.
790 Kuan, A. Gordon, A. Balmaseda, E. Harris, Symptomatic versus inapparent outcome in
791 repeat dengue virus infections is influenced by the time interval between infections and
792 study year. *PLoS Negl. Trop. Dis.* **7**, e2357 (2013).
- 793 35. A. Gordon, G. Kuan, J. C. Mercado, L. Gresh, W. Aviles, A. Balmaseda, E. Harris, The
794 Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic
795 dengue virus infections, 2004-2010. *PLoS Negl. Trop. Dis.* **7**, e2462 (2013).
- 796 36. T. K. Tsang, S. L. Ghebremariam, L. Gresh, A. Gordon, M. E. Halloran, L. C.
797 Katzelnick, D. P. Rojas, G. Kuan, A. Balmaseda, J. Sugimoto, E. Harris, I. M. Longini,
798 Jr., Y. Yang, Effects of infection history on dengue virus infection and pathogenicity. *Nat*
799 *Commun* **10**, 1246 (2019).
- 800 37. K. M. Soo, B. Khalid, S. M. Ching, H. Y. Chee, Meta-Analysis of Dengue Severity
801 during Infection by Different Dengue Virus Serotypes in Primary and Secondary
802 Infections. *PLoS One* **11**, e0154760 (2016).
- 803 38. R. Raut, K. S. Corbett, R. N. Tennekoon, S. Premawansa, A. Wijewickrama, G.
804 Premawansa, P. Mieczkowski, C. Ruckert, G. D. Ebel, A. D. De Silva, A. M. de Silva,
805 Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized
806 by human antibodies. *Proc. Natl. Acad. Sci. U S A* **116**, 227-232 (2019).
- 807 39. K. A. Dowd, C. R. DeMaso, T. C. Pierson, Genotypic Differences in Dengue Virus
808 Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus

- 809 Breathing. *mBio* **6**, e01559-01515 (2015).
- 810 40. H. Salje, M. T. Alera, M. N. Chua, T. Hunsawong, D. Ellison, A. Srikiatkachorn, R. G.
811 Jarman, G. D. Gromowski, I. Rodriguez-Barraquer, S. Cauchemez, D. A. T. Cummings,
812 L. Macareo, I. K. Yoon, S. Fernandez, A. L. Rothman, Evaluation of the extended
813 efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
814 *Nat. Med.* **27**, 1395-1400 (2021).
- 815 41. L. Lopez, R. E. Paul, V. M. Cao-Lormeau, X. Rodo, Considering waning immunity to
816 better explain dengue dynamics. *Epidemics* **41**, 100630 (2022).
- 817 42. K. B. Anderson, R. V. Gibbons, D. A. Cummings, A. Nisalak, S. Green, D. H. Libraty, R.
818 G. Jarman, A. Srikiatkachorn, M. P. Mammen, B. Darunee, I. K. Yoon, T. P. Endy, A
819 shorter time interval between first and second dengue infections is associated with
820 protection from clinical illness in a school-based cohort in Thailand. *J. Infect. Dis.* **209**,
821 360-368 (2014).
- 822 43. O. Brathwaite Dick, J. L. San Martin, R. H. Montoya, J. del Diego, B. Zambrano, G. H.
823 Dayan, The history of dengue outbreaks in the Americas. *Am. J. Trop. Med. Hyg.* **87**,
824 584-593 (2012).
- 825 44. H. C. Metsky, C. B. Matranga, S. Wohl, S. F. Schaffner, C. A. Freije, S. M. Winnicki, K.
826 West, J. Qu, M. L. Baniecki, A. Gladden-Young, A. E. Lin, C. H. Tomkins-Tinch, S. H.
827 Ye, D. J. Park, C. Y. Luo, K. G. Barnes, R. R. Shah, B. Chak, G. Barbosa-Lima, E.
828 Delatorre, Y. R. Vieira, L. M. Paul, A. L. Tan, C. M. Barcellona, M. C. Porcelli, C.
829 Vasquez, A. C. Cannons, M. R. Cone, K. N. Hogan, E. W. Kopp, J. J. Anzinger, K. F.
830 Garcia, L. A. Parham, R. M. G. Ramirez, M. C. M. Montoya, D. P. Rojas, C. M. Brown,
831 S. Hennigan, B. Sabina, S. Scotland, K. Gangavarapu, N. D. Grubaugh, G. Oliveira, R.

- 832 Robles-Sikisaka, A. Rambaut, L. Gehrke, S. Smole, M. E. Halloran, L. Villar, S. Mattar,
833 I. Lorenzana, J. Cerbino-Neto, C. Valim, W. Degraeve, P. T. Bozza, A. Gnirke, K. G.
834 Andersen, S. Isern, S. F. Michael, F. A. Bozza, T. M. L. Souza, I. Bosch, N. L. Yozwiak,
835 B. L. MacInnis, P. C. Sabeti, Zika virus evolution and spread in the Americas. *Nature*
836 **546**, 411-415 (2017).
- 837 45. Q. Zhang, K. Sun, M. Chinazzi, Y. Piontti A. Pastore, N. E. Dean, D. P. Rojas, S. Merler,
838 D. Mistry, P. Poletti, L. Rossi, M. Bray, M. E. Halloran, I. M. Longini, Jr., A.
839 Vespignani, Spread of Zika virus in the Americas. *Proc. Natl. Acad. Sci. U S A* **114**,
840 E4334-E4343 (2017).
- 841 46. G. Kuan, A. Gordon, W. Aviles, O. Ortega, S. N. Hammond, D. Elizondo, A. Nunez, J.
842 Coloma, A. Balmaseda, E. Harris, The Nicaraguan pediatric dengue cohort study: study
843 design, methods, use of information technology, and extension to other infectious
844 diseases. *Am. J. Epidemiol.* **170**, 120-129 (2009).
- 845 47. A. Gordon, G. Kuan, W. Aviles, N. Sanchez, S. Ojeda, B. Lopez, L. Gresh, A.
846 Balmaseda, E. Harris, The Nicaraguan pediatric influenza cohort study: design, methods,
847 use of technology, and compliance. *BMC Infect. Dis.* **15**, 504 (2015).
- 848 48. J. V. Zambrana, F. Bustos Carrillo, R. Burger-Calderon, D. Collado, N. Sanchez, S.
849 Ojeda, J. Carey Monterrey, M. Plazaola, B. Lopez, S. Arguello, D. Elizondo, W. Aviles,
850 J. Coloma, G. Kuan, A. Balmaseda, A. Gordon, E. Harris, Seroprevalence, risk factor,
851 and spatial analyses of Zika virus infection after the 2016 epidemic in Managua,
852 Nicaragua. *Proc. Natl. Acad. Sci. U S A* **115**, 9294-9299 (2018).
- 853 49. J. J. Waggoner, L. Gresh, A. Mohamed-Hadley, G. Ballesteros, M. J. Davila, Y. Tellez,
854 M. K. Sahoo, A. Balmaseda, E. Harris, B. A. Pinsky, Single-Reaction Multiplex Reverse

- 855 Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerg.*
856 *Infect. Dis.* **22**, 1295-1297 (2016).
- 857 50. A. Balmaseda, E. Sandoval, L. Perez, C. M. Gutierrez, E. Harris, Application of
858 molecular typing techniques in the 1998 dengue epidemic in Nicaragua. *Am. J. Trop.*
859 *Med. Hyg.* **61**, 893-897 (1999).
- 860 51. R. S. Lanciotti, C. H. Calisher, D. J. Gubler, G. J. Chang, A. V. Vorndam, Rapid
861 detection and typing of dengue viruses from clinical samples by using reverse
862 transcriptase-polymerase chain reaction. *J Clin Microbiol* **30**, 545-551 (1992).
- 863 52. J. J. Waggoner, G. Ballesteros, L. Gresh, A. Mohamed-Hadley, Y. Tellez, M. K. Sahoo,
864 J. Abeynayake, A. Balmaseda, E. Harris, B. A. Pinsky, Clinical evaluation of a single-
865 reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. *J. Clin.*
866 *Virol.* **78**, 57-61 (2016).
- 867 53. J. J. Waggoner, J. Abeynayake, M. K. Sahoo, L. Gresh, Y. Tellez, K. Gonzalez, G.
868 Ballesteros, A. M. Pierro, P. Gaibani, F. P. Guo, V. Sambri, A. Balmaseda, K.
869 Karunaratne, E. Harris, B. A. Pinsky, Single-reaction, multiplex, real-time rt-PCR for the
870 detection, quantitation, and serotyping of dengue viruses. *PLoS Negl. Trop. Dis.* **7**, e2116
871 (2013).
- 872 54. A. Balmaseda, J. V. Zambrana, D. Collado, N. Garcia, S. Saborio, D. Elizondo, J. C.
873 Mercado, K. Gonzalez, C. Cerpas, A. Nunez, D. Corti, J. J. Waggoner, G. Kuan, R.
874 Burger-Calderon, E. Harris, Comparison of Four Serological Methods and Two Reverse
875 Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. *J.*
876 *Clin. Microbiol.* **56**, 56(3):e01785-17 (2018).
- 877 55. A. Balmaseda, M. G. Guzman, S. Hammond, G. Robleto, C. Flores, Y. Tellez, E. Videa,

- 878 S. Saborio, L. Perez, E. Sandoval, Y. Rodriguez, E. Harris, Diagnosis of dengue virus
879 infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum
880 and saliva. *Clin. Diagn. Lab. Immunol.* **10**, 317-322 (2003).
- 881 56. A. Gordon, L. Gresh, S. Ojeda, L. C. Katzelnick, N. Sanchez, J. C. Mercado, G. Chowell,
882 B. Lopez, D. Elizondo, J. Coloma, R. Burger-Calderon, G. Kuan, A. Balmaseda, E.
883 Harris, Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua.
884 *PLoS Med.* **16**, e1002726 (2019).
- 885 57. Dustin Tingley, Teppei Yamamoto, Kentaro Hirose, Luke Keele, Kosuke Imai,
886 mediation: R Package for Causal Mediation Analysis. *J. of Stat. Soft.* **59**, (2014).
- 887 58. R Core Team. R: A Language and Environment for Statistical Computing (2023).
- 888 59. Vito M. R. Muggeo, Testing with a nuisance parameter present only under the
889 alternative: a score-based approach with application to segmented modelling. *J. of Stat.*
890 *Comp. and Sim.* **86**, 3059-3067 (2016).
- 891 60. Douglas Bates, Martin Mächler, Ben Bolker, Steve Walker, Fitting Linear Mixed-Effects
892 Models Using lme4. *J. of Stat. Soft.* **67**, 1- 48 (2015).
- 893 61. D. Alwin, R. Hauser, The Decomposition of Effects in Path Analysis. *American*
894 *Sociological Review*, **40**, 37-47 (1975).
- 895 62. Simon N. Wood, Yannig Goude, Simon Shaw, Generalized Additive Models for Large
896 Data Sets. *Journal of the Royal Statistical Society Series C: Applied Statistics* **64**, 139-
897 155 (2015).
- 898
- 899
- 900

901 **Acknowledgments:**

902 We thank the participants of the Pediatric Dengue Cohort Study and their families. We are
903 grateful to both past and current team members of the study, based at the Sócrates Flores Vivas
904 Health Center, the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y
905 Referencia, and the Sustainable Sciences Institute in Nicaragua for their commitment and
906 exceptional work.

907

908 **Funding:**

909 This work was supported by National Institutes of Health grants P01AI106695 (EH),
910 U19AI118610 (EH) and R01AI099631 (AB), Pediatric Dengue Vaccine Initiative grant VE-1
911 (EH), the Bill and Melinda Gates Foundation - FIRST grant (EH), and the Division of Intramural
912 Research of the National Institute of Allergy and Infectious Diseases (LCK).

913

914 **Author contributions:**

915 Conceptualization: JVZ, CMH, RAA, SB, LCK, EH

916 Methodology: JVZ, CMH, RAA, LCK, EH

917 Investigation: SA, CN, KG, DC, TM, GK, AB

918 Visualization: JVZ, CMH, RAA

919 Funding acquisition: AB, LCK, EH

920 Project administration: GK, AG, AB, EH

921 Supervision: LCK, EH

922 Writing – original draft: JVZ, CMH, RAA, LCK, EH

923 Writing – review & editing: All authors.

924

925 **Competing interests:**

926 EH's laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine
927 recipients. EH served on one-time advisory boards for Merck and Takeda. AG served on an RSV
928 vaccine scientific advisory board for Janssen.

929

930 **Data and materials availability:**

931 All data pertinent to this study can be found within the paper or the Supplementary Materials.
932 and the associated code is available for reference on Zenodo. After securing approval from the
933 UC Berkeley Committee for the Protection of Human Subjects, individual data for figure
934 reproduction could be shared with external researchers. For data access arrangements, please
935 contact EH at eharris@berkeley.edu. Standard data and material transfer agreements govern all
936 materials and data used in this study.

937

938 **Supplementary materials**

939 Fig. S1 to S3

940 Table S1 to S7

941

942

943 **FIGURE LEGENDS**

944

945 **Fig. 1. Nicaragua experienced a large dengue epidemic in 2022-2023 with co-circulation of**
946 **all four serotypes.** Monthly dengue and Zika cases (**A**), the proportion of individuals with
947 various infection histories (**B**), and DENV iELISA titer distribution (**C**) by epidemic year in the
948 Pediatric Dengue Cohort Study (2004-2022).

949

950 **Fig. 2. Prior infection history confers differential risk of symptomatic DENV1, DENV3 and**
951 **DENV4 and overall disease and disease severity.** Log-binomial and log-Poisson generalized
952 linear models (GLMs) were used to estimate the risk of any dengue case, a case caused by
953 DENV1, DENV2, DENV3, or DENV4, and Dengue with Warning Signs/Severe Dengue
954 (DwWS/SD) by DENV and ZIKV infection history in (**A**) the 2022-2023 epidemic or (**B**) all
955 years of the cohort study (2004-2023).

956

957 **Fig. 3. History of prior flavivirus infection exacerbates risk of symptomatic DENV2 and**
958 **DENV4 and overall disease and disease severity.** Linear mixed effects models were used to
959 estimate the risks of a symptomatic DENV infection (case) by any serotype or from and DENV1,
960 DENV2, DENV3, or DENV4 infection (**A**) and Dengue with Warning Signs/Severe Dengue
961 (DwWS/SD) and Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) (**B**) in the
962 prospective cohort study, 2004-2023 by immune status (naïve or flavivirus immune).

963

964 **Fig. 4. Risks of dengue differ by pre-existing anti-DENV antibody titers and infecting**
965 **serotype.** Linear mixed effects models were used to estimate the risk of any symptomatic DENV
966 infection, as well as a symptomatic infection caused by DENV1-4 by pre-existing DENV

967 iELISA titer during **(A)** the 2022-2023 epidemic or **(B)** all years of the cohort study (2004-2023).

968

969 **Fig. 5. DENV iELISA titer is a mediator that helps explain the relationship between**
970 **infection history and disease outcome. A)** Mediation path diagram and effects and contribution
971 of DENV iELISA titers (between 10 and 320) on disease risk attributed to prior flavivirus
972 infection. **B)** Mediation path diagram and effects and contribution of DENV iELISA titers
973 (>320) on disease risk attributed to prior flavivirus infection.

974

975 **Fig. 6. Primary DENV and ZIKV infections have distinct antibody dynamics as well as the**
976 **order of DENV or ZIKV infections.** Antibody kinetics in the Pediatric Dengue Cohort Study,
977 as measured using the DENV iELISA, are shown. Data are shown for 1 to up to 10 years for the
978 following infection histories: DENV-immune **(A)**, primary DENV **(B)**, primary ZIKV **(C)**,
979 DENV-DENV **(D)**, DENV-ZIKV **(E)**, ZIKV-DENV **(F)**, 2+DENV **(G)**, and 2+DENV-ZIKV
980 **(H)** infections. Individual trajectories and group Generalized Additive Model fits (black line;
981 95% CIs, gray shading) are shown.


982 **Table 1. Characteristics of participants in the Pediatric Dengue Cohort Study with**
 983 **documented infection histories in 2022-23.**
 984

Variable	Total Population		DENV cases					Dengue serology, N = 39 ¹	p-value ²
	N = 3,564 ¹	Overall, N = 374 ¹	DENV1, N = 139 ¹	DENV2, N = 9 ¹	DENV3, N = 54 ¹	DENV4, N = 133 ¹			
Age	10.4 (4.0)	11.0 (3.6)	10.6 (3.8)	10.2 (4.7)	11.1 (3.7)	11.9 (3.3)	9.7 (3.3)	0.003	
Sex								0.2	
F	1,768 (50%)	193 (52%)	64 (46%)	4 (44%)	25 (46%)	78 (59%)	22 (56%)		
M	1,794 (50%)	179 (48%)	74 (54%)	5 (56%)	29 (54%)	54 (41%)	17 (44%)		
DHF/DSS	3 (<0.1%)	3 (0.8%)	1 (0.7%)	0 (0%)	2 (3.7%)	0 (0%)	0 (0%)	0.2	
DwWS/SD	57 (1.6%)	57 (15%)	27 (19%)	1 (11%)	4 (7.4%)	23 (17%)	2 (5.1%)	0.076	
Time since last infection	5.50 (3.00)	5.81 (2.87)	5.90 (3.01)	6.25 (3.65)	6.41 (2.97)	5.35 (2.73)	6.18 (2.33)	0.049	
Geometric Mean Titer (iELISA)	665 (1,985)	390 (1,400)	314 (1,263)	6 (11)	58 (198)	684 (1,876)	154 (563)	<0.001	
Infection history									
Naive	1,559 (46%)	123 (35%)	55 (43%)	4 (50%)	19 (37%)	24 (19%)	21 (62%)		
DENV-immune	113 (3.3%)	12 (3.4%)	3 (2.3%)	0 (0%)	4 (7.8%)	4 (3.1%)	1 (2.9%)		
DENV	299 (8.8%)	33 (9.5%)	11 (8.6%)	0 (0%)	1 (2.0%)	20 (16%)	1 (2.9%)		
ZIKV	742 (22%)	110 (32%)	37 (29%)	4 (50%)	21 (41%)	41 (32%)	7 (21%)		
DENV-DENV	63 (1.8%)	12 (3.4%)	7 (5.5%)	0 (0%)	1 (2.0%)	4 (3.1%)	0 (0%)		
DENV-ZIKV	174 (5.1%)	25 (7.2%)	6 (4.7%)	0 (0%)	0 (0%)	17 (13%)	2 (5.9%)		
ZIKV-DENV	334 (9.8%)	25 (7.2%)	7 (5.5%)	0 (0%)	4 (7.8%)	13 (10%)	1 (2.9%)		
2+DENV	56 (1.6%)	2 (0.6%)	1 (0.8%)	0 (0%)	0 (0%)	1 (0.8%)	0 (0%)		
2+DENV-ZIKV	43 (1.3%)	6 (1.7%)	1 (0.8%)	0 (0%)	1 (2.0%)	3 (2.4%)	1 (2.9%)		
DENV-ZIKV-2+DENV	3 (<0.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
ZIKV-DENV-DENV	15 (0.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
2+DENV-ZIKV-DENV	11 (0.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		

¹Mean (SD); n (%)

²Kruskal-Wallis rank sum test; Fisher's exact test


985



medRxiv preprint doi: <https://doi.org/10.1101/2023.11.29.23299187>; this version posted November 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

A

Risk of dengue disease by prior DENV and ZIKV infection histories, 2022-23



B

Risk of dengue disease by prior DENV and ZIKV infection histories, 2004-23





Fig. 2

Risk Ratios

Risk of dengue disease by prior DENV/ZIKV infection histories, 2004-23



Risk of severe dengue disease by prior DENV/ZIKV infection histories, 2004-23





Fig. 3

medRxiv preprint doi: <https://doi.org/10.1101/2023.11.29.23299187>; this version posted November 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

A

Risk of dengue disease by preexisting DENV iELISA antibody titers, 2022-23



Risk of dengue disease by preexisting DENV iELISA titers, 2004-23




Fig. 4




Fig. 5




Fig. 6